{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:58:36Z","timestamp":1793149116766,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.medj.2025.100959","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:59:24Z","timestamp":1769615964000},"page":"100959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8569-2872","authenticated-orcid":false,"given":"Giovanni","family":"Musso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pinach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cassader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gambino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100959_bib1","doi-asserted-by":"crossref","first-page":"r1928","DOI":"10.1136\/bmj-2025-084950","article-title":"Diagnosis and management of metabolic dysfunction associated steatotic liver disease","volume":"391","author":"Musso","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2025.100959_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"67","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.medj.2025.100959_bib3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medj.2025.100959_bib4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medj.2025.100959_bib5","unstructured":"Food and Drug Administration. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Guidance for industry: draft guidance. December 2018 (https:\/\/www.fda.gov\/media\/119044\/download)."},{"key":"10.1016\/j.medj.2025.100959_bib6","series-title":"Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Chronic Non-infectious Liver Diseases","year":"2018"},{"key":"10.1016\/j.medj.2025.100959_bib7","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA."},{"key":"10.1016\/j.medj.2025.100959_bib8","unstructured":"First Treatment against Liver Scarring Caused by a Type of \u2018fatty Liver Disease\u2019 | European Medicines Agency (EMA)."},{"key":"10.1016\/j.medj.2025.100959_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100959_bib10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100959_bib11","unstructured":"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"key":"10.1016\/j.medj.2025.100959_bib12","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217785Orig1s000OtherR.pdf."},{"key":"10.1016\/j.medj.2025.100959_bib13","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217785Orig1s000IntegratedR.pdf."},{"key":"10.1016\/j.medj.2025.100959_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100959_bib15","unstructured":"EMA, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rezdiffra."},{"key":"10.1016\/j.medj.2025.100959_bib16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/dom.16065","article-title":"Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction-associated steatotic liver disease: Post hoc analysis of three randomised controlled trials","volume":"27","author":"Armstrong","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.medj.2025.100959_bib17","unstructured":"ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT02970942?tab=results."},{"key":"10.1016\/j.medj.2025.100959_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17122","article-title":"Value-Based Pricing of Resmetirom for Metabolic Dysfunction\u2013Associated Steatotic Liver Disease","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.medj.2025.100959_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/liv.15759","article-title":"Thyroid hormone receptor alpha modulates fibrogenesis in hepatic stellate cells","volume":"44","author":"Manka","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.medj.2025.100959_bib20","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/DMSO.S313503","article-title":"Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease","volume":"14","author":"Du","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.medj.2025.100959_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.33549\/physiolres.935453","article-title":"Thyroid-Stimulating Hormone: An Important Target for the Prevention of Nonalcoholic Fatty Liver Disease","volume":"74","author":"Wang","year":"2025","journal-title":"Physiol. Res."},{"key":"10.1016\/j.medj.2025.100959_bib22","doi-asserted-by":"crossref","DOI":"10.1530\/JME-25-0096","article-title":"Dysregulation of hepatic deiodinase type I in metabolically associated steatotic liver disease","volume":"75","author":"Lopez-Alcantara","year":"2025","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.medj.2025.100959_bib23","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med."},{"key":"10.1016\/j.medj.2025.100959_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1210\/en.2012-1937","article-title":"GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE\u2212\/\u2212 mice","volume":"154","author":"Panjwani","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2025.100959_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.medj.2025.100959_bib26","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3945\/ajcn.112.040006","article-title":"Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort","volume":"96","author":"Bo","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.medj.2025.100959_bib27","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/ph18091321","article-title":"Present and Future Perspectives in the Treatment of Liver Fibrosis","volume":"18","author":"Cerrito","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.medj.2025.100959_bib28","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.3390\/cancers17162600","article-title":"Repurposing GLP-1 Receptor Agonists: A Perspective on Epigenetic Strategies to Combat Fibrosis and Hepatocellular Carcinoma in the Aged Liver","volume":"17","author":"Hanna","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.medj.2025.100959_bib29","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf116","article-title":"Epigenomic Modulators and Thyroid Hormone Receptor \u03b2 Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer","volume":"166","author":"Rustad","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.medj.2025.100959_bib30","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0231","article-title":"Decreased hepatic thyroid hormone signaling in systemic and liver-specific but not brain-specific accelerated aging due to DNA repair deficiency in mice","volume":"12","author":"Barnhoorn","year":"2023","journal-title":"Eur. Thyroid J."},{"key":"10.1016\/j.medj.2025.100959_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000495170","article-title":"Adipose TSHB in Humans and Serum TSH in Hypothyroid Rats Inform About Cellular Senescence","volume":"51","author":"Moreno-Navarrete","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.medj.2025.100959_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100700","article-title":"microRNA-122 inhibits hepatic stellate cell proliferation and activation in vitro and represses carbon tetrachloride-induced liver cirrhosis in mice","volume":"27","author":"Ma","year":"2022","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.medj.2025.100959_bib33","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.gendis.2022.08.013","article-title":"Interplays of liver fibrosis-associated microRNAs: Molecular mechanisms and implications in diagnosis and therapy","volume":"10","author":"Li","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.medj.2025.100959_bib58","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1194\/jlr.M075028","article-title":"TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD","volume":"58","author":"Musso","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.medj.2025.100959_bib34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.medj.2025.100959_bib51","first-page":"2019","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.medj.2025.100959_bib35","unstructured":"U.S. Food and Drug Administration."},{"key":"10.1016\/j.medj.2025.100959_bib36","unstructured":"Medicines | European Medicines Agency (EMA)."},{"key":"10.1016\/j.medj.2025.100959_bib37","unstructured":"Pharmaceuticals and Medical Devices Agency."},{"key":"10.1016\/j.medj.2025.100959_bib38","unstructured":"https:\/\/methods.cochrane.org\/risk-bias-2 The Cochrane Collaboration. Accessed at www.cochrane-handbook.org on 14 June 2025."},{"key":"10.1016\/j.medj.2025.100959_bib39","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jclinepi.2017.12.004","article-title":"Recommendations for assessing the risk of bias in systematic reviews of health-care interventions","volume":"97","author":"Viswanathan","year":"2018","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.medj.2025.100959_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1740774515602688","article-title":"Fallacies of last observation carried forward analyses","volume":"13","author":"Lachin","year":"2016","journal-title":"Clin. Trials"},{"key":"10.1016\/j.medj.2025.100959_bib41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JRS-2012-0574","article-title":"Sponsorship bias in clinical research","volume":"24","author":"Lexchin","year":"2012","journal-title":"Int. J. Risk Saf. Med."},{"key":"10.1016\/j.medj.2025.100959_bib42","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005053-200209000-00002","article-title":"Design and reporting modifications in industry sponsored comparative psychopharmacology trials","volume":"190","author":"Safer","year":"2002","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.medj.2025.100959_bib43","year":"2010"},{"key":"10.1016\/j.medj.2025.100959_bib44","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/jama.299.15.1813","article-title":"Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation","volume":"299","author":"Psaty","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100959_bib45","first-page":"557","article-title":"Medical specialists and pharmaceutical industry-sponsored research: A survey of the Australian experience","volume":"182","author":"Henry","year":"2005","journal-title":"MJA (Med. J. Aust.)"},{"key":"10.1016\/j.medj.2025.100959_bib46","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.295.14.1645","article-title":"Constraints on publication rights in industry-initiated clinical trials","volume":"295","author":"G\u00f8tzsche","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.medj.2025.100959_bib47","unstructured":"https:\/\/revman.cochrane.org\/info"},{"key":"10.1016\/j.medj.2025.100959_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-018-0618-3","article-title":"Likelihood-based random-effects meta-analysis with few studies: empirical and simulation studies","volume":"19","author":"Seide","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.medj.2025.100959_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/sim.2528","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat. Med."},{"key":"10.1016\/j.medj.2025.100959_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.medj.2025.100959_bib52","series-title":"Handbook for Grading the Quality of Evidence and the Strength of Recommendations using the GRADE Approach","year":"2013"},{"key":"10.1016\/j.medj.2025.100959_bib53","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.medj.2025.100959_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jclinepi.2022.07.014","article-title":"GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach","volume":"150","author":"Zeng","year":"2022","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.medj.2025.100959_bib55","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence - publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:16:35Z","timestamp":1784600195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025003861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666634025003861"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100959","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100959"}}